Sec Form 4 Filing - ELMS STEVE @ Cidara Therapeutics, Inc. - 2015-04-20

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ELMS STEVE 2. Issuer Name and Ticker or Trading Symbol Cidara Therapeutics, Inc. [ CDTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 888 SEVENTH AVE, 29TH FL 3. Date of Earliest Transaction (MM/DD/YY) 04/20/2015 (Street) NEW YORK, NY10106 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 703,092 I By Seachaid Pharmaceuticals, LLC. ( 1 ) ( 4 ) Common Stock 04/20/2015 04/20/2015 C( 2 ) 351,518 A 351,518 I By Aisling Capital II, L.P. ( 3 ) ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Convertible Preferred Stock < sup>( 2 ) 04/20/2015 04/20/2015 C 8,928,572 ( 2 ) ( 2 ) Common Stock 351,518 $ 0 0 I By Aisling Capital II, L.P. ( 3 ) ( 4 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ELMS STEVE 888 SEVENTH AVE 29TH FL NEW YORK, NY10106 X Signatures /s/ Steve Elms 04/22/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares of common stock, par value $0.0001 per share (the "Common Shares") of Cidara Therapeutics, Inc. (the "Issuer") are held directly by Seachaid Pharmaceuticals, LLC. ("Seachaid"). ( 2 )In connection with the Issuer's initial public offering on April 20, 2015, shares of preferred stock, par value $0.0001 per share (the "Preferred Shares") automatically converted into Common Shares on a 25.4-to-1 basis. ( 3 )Common Shares are directly held by Aisling Capital II, LP ("Aisling"). ( 4 )The investment committee of Aisling holds sole voting and dispositive power over the Common Shares held by Seachaid and Aisling. Aisling is a majority-owner of Seachaid. Aisling Capital Partners LP ("Aisling GP") is the general partner of Aisling and Aisling Capital Partners LLC ("Aisling Partners") is the general partner of Aisling GP. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling and Seachaid. Each of the Reporting Persons disclaims beneficial ownership of the Common Shares, except to the extent of such person's pecuniary interest.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.